Epidermal growth factor (EGF), hepatocyte growth factor (HGF), and vascular endothelial growth factor (VEGF) regulate angiogenesis and cell growth in the developing brain. EGF, HGF, and VEGF modulate the activity of the mammalian target of rapamycin (mTOR) cascade, a pathway regulating cell growth that is aberrantly activated in tuberous sclerosis complex (TSC). We hypothesized that expression of EGF, HGF, VEGF, and their receptors EGFR, c-Met, and Flt-1, respectively, would be altered in TSC. We show by cDNA array and immunohistochemical analysis that EGF, EGFR, HGF, c-Met, and VEGF, but not Flt-1, mRNA, and protein expression was up-regulated in Tsc1 conditional knockout (Tsc1 GFAP CKO) mouse cortex. Importantly, these alterations closely predicted enhanced expression of these proteins in tuber and subependymal giant cell astrocytoma (SEGA) specimens in TSC. Expression of EGF, EGFR, HGF, c-Met, and VEGF protein, as well as hypoxia inducible factor-1␣, a transcription factor that regulates VEGF levels and is also modulated by mTOR cascade activity, was enhanced in SEGAs (n ؍ 6) and tubers (n ؍ 10) from 15 TSC patients. Enhanced expression of these growth factors and growth factor receptors in human SEGAs and tubers and in the Tsc1 GFAP CKO mouse may account for enhanced cellular growth and proliferation in tubers and SEGAs and provides potential target molecules for therapeutic development in TSC. Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that results from mutations in the TSC1 or TSC2 genes, which encode TSC1 and TSC2 proteins, respectively. 1,2 Many individuals with TSC exhibit cognitive disability and autism, 3 and more than 75% of TSC patients develop seizures. 4 -6 Examination of the brain demonstrates cortical tubers and subependymal nodules (SENs) in more than 70% of TSC patients. Tubers are developmental malformations of the cerebral cortex highly associated with epilepsy and neurocognitive abnormalities. SENs are nodular lesions (typically smaller than 1 cm) located on the surfaces of the lateral and third ventricles. In approximately 10% to 20% of TSC patients, subependymal giant cell astrocytomas (SEGAs) arise within the lateral ventricles, often near the foramen of Monro. SEGAs are World Health Organization grade I tumors with low mitotic index as evidenced by Ki-67 immunoreactivity suggestive of slow cellular proliferation. 7,8 It is widely believed that SENs grow to form SEGAs, although the molecular mechanisms governing transformation from SEN to SEGA are unknown. 9 Both SENs and SEGAs consist of dysmorphic glial cells, enlarged giant cells (GCs), and spindle-shaped cells of unknown phenotype. 10,11 Cellular immunoreactivity for glial fibrillary acidic protein (GFAP), neurofilament, S-100, neuron-specific enoSupported by NS045877, NS045021, and Department of Defense CDMRP-TSC Program grants (P.B.C.); the National Epilepsy Fund -"Power of the Small," Hersenstichting Nederland (NEF 02-10 and NEF 05-11) and Stichting Michelle (M06.011) (E.A.); and AOA and AANS medical s...